StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Belsomra (suvorexant by Quarter

Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. reported growth YoY (%) (%)

QuarterlyAnnual

Merck Belsomra (suvorexant: 18.0% in Q4 2025, up 30.0 pts from a year earlier.

Latest, Q4 2025
18.0%
Period ended Dec 31, 2025
Change on a year earlier
+30.0 pts
-12.0% in Q4 2024
History
27 quarters
Since Q1 2018
Sources
27
Documents cited below

Where the Q4 2025 figure comes from

“|| Belsomra | 49 | 45 | 8 | 22 | 19 | 18 | 27 | 26 | 1”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBelsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. reported growth YoY (%) (%)Year on yearSource
Q4 2025Dec 31, 202518.0%+30.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202540.0%+52.0 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025-1.0%+11.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 2025-10.0%-1.0 ptsForm 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 2024-12.0%-22.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024-12.0%-24.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 2024-12.0%-22.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-9.0%–Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202310.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202312.0%+25.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 202310.0%-24.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q3 2022Sep 30, 2022-13.0%–Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202234.0%–Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 202213.0%+46.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 202158.0%–Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q1 2021Mar 31, 2021-33.0%-47.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗

Cite this data

StockData. (2026). Merck Belsomra (suvorexant (%), quarterly Q1 2018–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-belsomra-us-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.